SG191602A1 - Reoviruses having modified sequences - Google Patents

Reoviruses having modified sequences Download PDF

Info

Publication number
SG191602A1
SG191602A1 SG2013040027A SG2013040027A SG191602A1 SG 191602 A1 SG191602 A1 SG 191602A1 SG 2013040027 A SG2013040027 A SG 2013040027A SG 2013040027 A SG2013040027 A SG 2013040027A SG 191602 A1 SG191602 A1 SG 191602A1
Authority
SG
Singapore
Prior art keywords
leu
ser
ala
val
asp
Prior art date
Application number
SG2013040027A
Other languages
English (en)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG191602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of SG191602A1 publication Critical patent/SG191602A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013040027A 2007-03-12 2008-03-11 Reoviruses having modified sequences SG191602A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US98956807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
SG191602A1 true SG191602A1 (en) 2013-07-31

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013040027A SG191602A1 (en) 2007-03-12 2008-03-11 Reoviruses having modified sequences

Country Status (16)

Country Link
US (5) US7803385B2 (enExample)
EP (2) EP2132315B1 (enExample)
JP (1) JP5577103B2 (enExample)
KR (1) KR101647843B1 (enExample)
CN (1) CN103710359A (enExample)
AR (1) AR066395A1 (enExample)
AU (1) AU2008226291B2 (enExample)
CA (1) CA2678721C (enExample)
DK (1) DK2132315T3 (enExample)
ES (1) ES2548442T3 (enExample)
IL (4) IL200353A (enExample)
MX (2) MX2009009598A (enExample)
SG (1) SG191602A1 (enExample)
TW (1) TW200904979A (enExample)
WO (1) WO2008110004A1 (enExample)
ZA (1) ZA200905951B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク,インコーポレーテッド 改変配列を有するレオウイルス
EP2211880A4 (en) * 2007-10-22 2012-11-14 Oncolytics Biotech Inc TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
EP2304024A2 (en) * 2008-06-26 2011-04-06 Biomune Company Avian reoviridae
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
CA2776386C (en) * 2009-10-02 2018-02-27 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
MX337348B (es) * 2011-04-29 2016-02-29 Oncolytics Biotech Inc Metodos para purificar virus utilizando cromatografia de permeacion en gel.
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2020227245A1 (en) * 2019-05-03 2020-11-12 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
WO2022139490A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 변형 레오바이러스 및 이의 용도
EP4268837A4 (en) * 2020-12-22 2025-05-07 Virocure, Inc. NEW MODIFIED REOVIRUS AND ITS USE
US20250154204A1 (en) * 2021-09-24 2025-05-15 Virocure, Inc. Novel reovirus-based vaccine platform and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2189162T3 (da) * 2000-11-09 2014-02-03 Oncolytics Biotech Inc Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
EP1339736A2 (en) * 2000-12-01 2003-09-03 University Of Ottawa Oncolytic virus
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2571844A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing minus-strand rna virus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク,インコーポレーテッド 改変配列を有するレオウイルス
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2012075379A2 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂

Also Published As

Publication number Publication date
DK2132315T3 (en) 2015-10-19
US20110020288A1 (en) 2011-01-27
KR101647843B1 (ko) 2016-08-11
US10039827B2 (en) 2018-08-07
EP2132315A4 (en) 2011-10-05
US10596260B2 (en) 2020-03-24
EP2952583A1 (en) 2015-12-09
MX346950B (es) 2017-04-06
US7803385B2 (en) 2010-09-28
EP2132315B1 (en) 2015-07-15
KR20090125103A (ko) 2009-12-03
IL200353A0 (en) 2011-08-01
US20200237917A1 (en) 2020-07-30
US8691241B2 (en) 2014-04-08
CN103710359A (zh) 2014-04-09
AU2008226291A2 (en) 2009-10-08
TW200904979A (en) 2009-02-01
AU2008226291B2 (en) 2014-01-16
US11246930B2 (en) 2022-02-15
AR066395A1 (es) 2009-08-19
HK1132761A1 (en) 2010-03-05
IL200353A (en) 2017-07-31
US20140186301A1 (en) 2014-07-03
CA2678721C (en) 2018-02-13
MX2009009598A (es) 2009-09-21
JP5577103B2 (ja) 2014-08-20
IL221701A0 (en) 2012-10-31
US20080226602A1 (en) 2008-09-18
US20090035278A2 (en) 2009-02-05
JP2010520758A (ja) 2010-06-17
ZA200905951B (en) 2010-11-24
CA2678721A1 (en) 2008-09-18
ES2548442T3 (es) 2015-10-16
WO2008110004A1 (en) 2008-09-18
IL221702A0 (en) 2012-10-31
IL221700A0 (en) 2012-10-31
EP2132315A1 (en) 2009-12-16
US20180344853A1 (en) 2018-12-06
AU2008226291A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
US11246930B2 (en) Reoviruses having modified sequences
AU2008253505B2 (en) Mutant reoviruses and methods of making and using
EP1309672A1 (en) Method of producing infectious reovirus
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
EP1424897A2 (en) Compositions and methods for treatment of cancer
CN109419818B (zh) 一种用于治疗肿瘤的埃可病毒
AU2009253683B2 (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
AU2013201835A1 (en) Reoviruses having modified sequences
CN101627122A (zh) 具有修饰的序列的呼肠孤病毒
CN103882057B (zh) 携带p21ras单链抗体基因肿瘤特异性腺病毒载体的构建及其应用
HK1132761B (en) Reoviruses having modified sequences
CN113667016A (zh) 一种构建冠状病毒抗体的平台
HK1136006B (en) Mutant reoviruses and methods of making and using